ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1362

Evaluation of Spondyloarthritis activity  by the Patients and the Physicians: ASDAS, Basdai, PASS and Flare

Marie Godfrin-Valnet1, Clément Prati2, Marc Puyraveau3, Eric Toussirot4, Helene Letho-Gyselinck5 and Daniel Wendling5, 1Rheumatology, CHU, Besançon, France, 2Service de Rhumatologie, CHU J Minjoz, Besancon, France, 3Clinical Methodology Center, CHU, Besançon, France, 4Université de Franche Comté , CHRU, CIC Biotherapy 506 and Rheumatology and EA 4266 Pathogens and Inflammation, Besançon, France, 5Service de Rhumatologie, Minjoz University Hospital, Besancon, France

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Spondylarthropathy

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Objectives: to define thresholds of the ASDAS corresponding to the PASS (Pateint Acceptable Symptomatic State) and to the thresholds of activity of the disease through what the patients feel. Correlate these levels of activity to the presence of a depressive syndrome and determine a threshold ASDAS and BASDAI corresponding to a flare in spondyloarthritis (SpA).

Methods:

A prospective study of SpA patients (ASAS criteria) from February 2011 until February 2012. Various scores (BASDAI, ASDAS, BASFI) as well as the evaluation of the PASS and the depressive syndrome were measured. Determination of ASDAS thresholds corresponding to the PASS, to the various thresholds of activity according to the patients, and to flare was performed using ROC curves. The Kappa coefficient was calculated to estimate the correlation between the physician’s and the patient’s evaluation of the flare.

Results:

200 SpA patients, mean age 44.4 ± 12.5 years (duration 12.9 ± 10.5 years) were included. The average scores were respectively 4.1 ± 2.2 for the BASDAI and of 2.4 ± 1 for the ASDAS-CRP and of 3.3 ± 2.7 for the BASFI. 58.9 % of the patients were considered in PASS. The PASS corresponded to a BASDAI ≤ 4.1 and to an ASDAS-CRP ≤2.3. Concerning the impression of the disease by the patients: a weakly active disease corresponded to a BASDAI ≤3.8 and to an ASDAS-CRP ≤2.3, and a strongly active disease in a BASDAI >5.2 and an ASDAS-CRP > 3.1. When the disease was considered as strongly active, 64.5 % of patients had a score of severe depressive syndrome on Beck’s scale. A flare was considered by 36.9 % of the patients versus 28.3 % of the physicians. The threshold BASDAI “flare” was ≥5.2 and the threshold ASDAS-CRP “flare” was ≥2.3. The concordance between the evaluation of the flare according to the physician and the patient was good (Kappa: 0.61).

Conclusion:

Our results report a significant link between the level of activity of the disease and the severity of the depressive syndrome. Our study confirms a good concordance between the BASDAI and the ASDAS. Thresholds of BASDAI and ASDAS are proposed for PASS and flare in SpA.


Disclosure:

M. Godfrin-Valnet,
None;

C. Prati,
None;

M. Puyraveau,
None;

E. Toussirot,
None;

H. Letho-Gyselinck,
None;

D. Wendling,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/evaluation-of-spondyloarthritis-activity-by-the-patients-and-the-physicians-asdas-basdai-pass-and-flare/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology